Acute Pain Pipeline Drugs

(Albany, US) DelveInsight has launched a new report on “Acute Pain Pipeline Insight, 2020”.

Acute Pain Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Pain market. A detailed picture of the Acute Pain pipeline landscape is provided, which includes the disease overview and Acute Pain treatment guidelines.

The assessment part of the report embraces in-depth Acute Pain commercial assessment and clinical assessment of the Acute Pain pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Pain collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The key players in Acute Pain market are:

  • IBSA Institut Biochimique SA/ Teikoku Seiyaku
  • AcelRx Pharmaceuticals
  • KemPharm
  • AcelRx Pharmaceuticals
  • Iroko Pharmaceuticals
  • EGALET
  • King Pharmaceuticals, Inc.
  • Pacira Pharmaceuticals
  • Depomed
  • Ortho-McNeil-Janssen
  • Mallinckrodt
  • Janssen Pharms
  • Allergan
  • Trevena
  • Heron Therapeutics
  • Charleston Laboratories
  • Menarini Group
  • Mundipharma Research GmbH & Co KG/Laboratorios del Dr Esteve, S.A.
  • Cara Therapeutics
  • Boehringer Ingelheim
  • Boehringer Ingelheim
  • Medical Developments International Limited
  • Concentric Analgesics
  • Vertex Pharmaceuticals Incorporated
  • Charleston Laboratories
  • Neurana Pharmaceuticals
  • Neumentum Pharmaceuticals

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight            

Acute pain is defined as “an expected physiologic experience to injurious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries.”

The presence of pain often means that something is wrong. Each individual is the best judge of his or her own pain. There are different types of pain; basically, they are categorized into two forms, i.e., acute pain and chronic pain. Acute pain usually comes on suddenly and is caused by something specific. It is sharp in quality. Acute pain usually does not last longer than six months. It goes away when there is no longer an underlying cause for the pain.

On the other hand, chronic pain is pain that is ongoing and usually lasts longer than six months. This type of pain can continue even after the injury or illness that caused it has healed or gone away. Pain signals remain active in the nervous system for weeks, months, or years.

Since acute pain is a broad term, the symptoms associated with acute pain vary diversely. The most common symptoms that may be associated with acute pain include flu-like symptoms (fever, chills, sore throat, cough), fatigue, numbness, muscle spasms, insomnia, weight loss, anxiety, depression.

“The market size is expected to increase during the study period (2017–2030).”

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight

The launch of the emerging therapies is expected to significantly impact Acute Pain treatment scenario in the upcoming years:-

Drugs covered:

  • Licart (Diclofenac Epolamine)
  • Dsuvia (Sufentanil)
  • Apadaz
  • Zalviso
  • Tivorbex (Indomenthacin)
  • Zorvolex (Diclofenac)
  • Oxecta
  • Exparel
  • Zipsor
  • Nucynta
  • Ofirmev
  • Ultracet
  • Ubrogepant
  • Oliceridine injection (TRV130)
  • HTX-011
  • CL-108
  • Dexketoprofen Tramadol
  • MR308
  • CR845
  • Capsaicin/Diclofenac
  • Ibuprofen
  • Methoxyflurane
  • CA-008
  • VX-150
  • CL-H1T
  • Tolperisone
  • NTM-001

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight

Table of Contents:

  1. Report Introduction
  2. Acute Pain 

2.1. Overview

2.2. History

2.3. Acute Pain Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Acute Pain Diagnosis

2.6.1. Diagnostic Guidelines

  1. Acute Pain Current Treatment Patterns

3.1. Acute Pain Treatment Guidelines

  1. Acute Pain – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Acute Pain companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Acute Pain Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Acute Pain Acquisition Analysis

  1. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

  1. Acute Pain Late Stage Products (Phase-III)
  2. Acute Pain Mid Stage Products (Phase-II)
  3. Early Stage Products (Phase-I)
  4. Pre-clinical Products and Discovery Stage Products
  5. Inactive Products
  6. Dormant Products
  7. Acute Pain Discontinued Products
  8. Acute Pain Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report?

  1. Acute Pain Key Companies
  2. Acute Pain Key Products
  3. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

  1. Acute Pain Unmet Needs
  2. Acute Pain Future Perspectives
  3. Acute Pain Analyst Review  
  4. Appendix
  5. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Request for Detailed TOC : https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight

Related Reports:

Acute Pain – Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s “Acute Pain – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acute Pain, historical and forecasted epidemiology as well as the Acute Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Acute Pain – Epidemiology Forecast to 2030

DelveInsight’s ‘Acute Pain – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Acute Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: [email protected]
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

By sthakur